Auristatin F is primarily utilized in the development of antibody-drug conjugates (ADCs), which are targeted cancer therapies. It functions as a potent cytotoxic agent that inhibits cell division by disrupting microtubule dynamics. When conjugated to monoclonal antibodies, it is delivered directly to cancer cells, minimizing damage to healthy tissues. This targeted approach enhances the efficacy of cancer treatment while reducing systemic toxicity. Auristatin F is particularly valuable in treating hematologic malignancies and solid tumors, offering a promising avenue for precision medicine in oncology.